Repaglinide 1mg Tablet Franchise in Mumbai Maharashtra

Repaglinide Antidiabetic PCD Pharma Opportunity in Delhi NCR

Repaglinide Tablet Supplier in Chennai Tamil Nadu

Repaglinide 1mg PCD Franchise in Kolkata West Bengal

Type 2 Diabetes Medicine Distributor in Bangalore Karnataka
Repaglinide Tablet Exporter and Manufacturer in Hyderabad Telangana

Home/Products /repaglinide-ip-1mg-tablet

Repacept 1 Tablet

Composition : Repaglinide (1mg)

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹1/-

Repacept Tablet contains Repaglinide (1mg), an oral antidiabetic medication that helps regulate postprandial blood glucose levels in patients with type 2 diabetes mellitus. It works by stimulating the pancreas to release insulin, thereby lowering blood sugar after meals.

Repaglinide belongs to the meglitinide class of drugs, known for their rapid action and short duration, making them particularly effective for controlling meal-related glucose spikes. This property allows for flexible dosing and minimizes the risk of hypoglycemia compared to other agents.

Repacept Tablet is part of the antidiabetic and endocrinology segment, widely recommended for improving glycemic control in adults with type 2 diabetes, especially when diet and exercise alone are insufficient.

For pharmaceutical distributors and franchise owners, Repacept Tablet offers an excellent PCD pharma franchise and third-party manufacturing opportunity in the growing diabetic care market. Its strong clinical efficacy and consistent demand ensure long-term business growth and sustainability across India.

Read More

About the Product

Repacept Tablet contains Repaglinide (1mg), an oral antidiabetic medication that helps regulate postprandial blood glucose levels in patients with type 2 diabetes mellitus. It works by stimulating the pancreas to release insulin, thereby lowering blood sugar after meals.

Repaglinide belongs to the meglitinide class of drugs, known for their rapid action and short duration, making them particularly effective for controlling meal-related glucose spikes. This property allows for flexible dosing and minimizes the risk of hypoglycemia compared to other agents.

Repacept Tablet is part of the antidiabetic and endocrinology segment, widely recommended for improving glycemic control in adults with type 2 diabetes, especially when diet and exercise alone are insufficient.

For pharmaceutical distributors and franchise owners, Repacept Tablet offers an excellent PCD pharma franchise and third-party manufacturing opportunity in the growing diabetic care market. Its strong clinical efficacy and consistent demand ensure long-term business growth and sustainability across India.

Common side effects include mild hypoglycemia, headache, dizziness, and gastrointestinal discomfort. Rarely, allergic reactions, visual disturbances, or liver enzyme changes may occur. Consult your doctor if any side effects persist or worsen.

Repacept Tablet is indicated for the treatment of type 2 diabetes mellitus in adults, particularly when blood glucose levels are not adequately controlled by diet and exercise alone. It is especially useful for patients who experience elevated blood sugar levels after meals.

Take Repacept Tablet before meals as prescribed by your physician. Skip the dose if you skip a meal to prevent hypoglycemia. Maintain regular blood glucose monitoring and follow a healthy lifestyle plan. Inform your doctor if you have liver disease or are taking other antidiabetic medications.

Store Repacept Tablet in a cool, dry place below 25°C, away from moisture and direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation